Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Abemaciclib Plus Endocrine Therapy Approved by FDA for Early Breast Cancer
Breakthrough Therapy Designation Granted for T-DXd in HER2-Positive Breast Cancer
ESMO 2021: Interim Phase II Results With Dalpiciclib Plus Pyrotinib in HER2-Positive Breast Cancer
ESMO 2021: Subgroup Analysis of Asian Patients Treated With T-DM1 for Breast Cancer
ESMO 2021: Update From KEYNOTE-355 on Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ESMO 2021: Neoadjuvant Giredestrant Versus Anastrozole in Postmenopausal Women With Early Breast Cancer
ESMO 2021: Long-Term Overall Survival With Letrozole Plus Ribociclib in Advanced Breast Cancer
ESMO 2021: DESTINY-Breast03 Trial of T-DXd Versus T-DM1 in HER2-Positive Breast Cancer
ESMO 2021: How Does 6 Months of Trastuzumab Measure Up to Longer Treatment in Early Breast Cancer?
ESMO 2021: COVID-19 Vaccination in Patients With Breast Cancer
Are Genetic Alterations Linked to Resistance to Antibody-Drug Conjugate in Triple-Negative Breast Cancer?
Long-Term Survival Update From Secondary Analysis of Stockholm Tamoxifen Trial
Can Statins Improve Outcomes in Patients With Triple-Negative Breast Cancer?
COVID-19 and Breast Cancer: Focus on Building Vaccine Acceptance
Manufacturer Withdraws Atezolizumab’s U.S. Indication in Triple-Negative Breast Cancer
FDA Issues Caution Statement on Use of Robotically Assisted Surgical Devices for Mastectomy
Postmenopausal Women With Breast Cancer: How Many Years of Adjuvant Endocrine Therapy Is Necessary?
Stromal Platelet-Derived Growth Factor Receptor-Beta Expression Biomarker for Early Breast Cancer
Preventing Trastuzumab-Induced Cardiotoxicity in Breast Cancer: Lisinopril or Carvedilol?
Patient Survey on Dosage Strategies and Tolerability of Breast Cancer Therapy
Estrogen Receptor Antagonist Under Study for Locally Advanced or Metastatic Breast Cancer
Managing Breast Cancer in Older Adults: An Updated International Policy Review
Can Serum Levels of Vitamin D at Diagnosis Predict Breast Cancer Prognosis?
Pembrolizumab Combination Receives FDA Approval in Triple-Negative Breast Cancer
FDA Brief: Trilaciclib Plus Chemotherapy Granted Fast Track Designation in Triple-Negative Breast Cancer
Early Results for Novel Combination in Metastatic Breast Cancer
Early-Phase Trials of Novel Antibody-Drug Conjugate in HER2-Overexpressed Solid Tumors
Pooled Analysis of HER2-Targeting Antibody-Drug Conjugate in Metastatic Breast Cancer
Fulvestrant With or Without Venetoclax in Locally Advanced or Metastatic Breast Cancer
Body Mass Index and Breast Cancer Outcomes by Racial Ancestry
Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer With Brain Metastases
ASCO 2021: Neoadjuvant Talazoparib Active in Germline BRCA1/2-Mutated HER2-Negative Breast Cancer
Patient With Breast Cancer Successfully Treated With Immunotherapy in Thailand Hospital
ASCO 2021: MONALEESA-3 Survival Update of Ribociclib/Fulvestrant for Advanced Breast Cancer
Updated ASCO Guideline for Managing Hereditary Breast Cancer
ASCO 2021: Long-Term Survival With Palbociclib Plus Fulvestrant in Advanced Breast Cancer
Treatment Implications of Breast Tumors’ Switch to HER2-Low Status in Recurrence
Implications of Symptom Burden Among Breast Cancer Survivors
ASCO 2021: Adjuvant Durvalumab Treatment for Triple-Negative Breast Cancer
ASCO 2021: Novel CDK4/6 Inhibitor Plus Fulvestrant Focus of Phase III Trial in Advanced Breast Cancer
ASCO 2021: Adjuvant Capecitabine Versus Platinum-Based Chemotherapy for Residual Triple-Negative Breast Cancer
ASCO 2021: COVID-19 Outcomes and Breast Cancer by Racial/Ethnic Group
Androgen Receptor–Targeting Agent Under Study in Metastatic Disease
ASCO 2021: Survival Outcomes With De-escalated Neoadjuvant Treatment of Early Breast Cancer
ASCO 2021: OlympiA Trial of Adjuvant Olaparib After Chemotherapy for Early-Stage Breast Cancer
ESMO Breast 2021: Atezolizumab Plus Carboplatin for Metastatic Invasive Lobular Cancer
ESMO Breast 2021: Distinct Gene Signatures Associated With Pathologic Complete Response
ESMO Breast 2021: Does Clinical Benefit From Endocrine Therapy Differ by Risk Group?
Adding Oral Alisertib to Weekly Paclitaxel for Metastatic Breast Cancer
ESMO Breast 2021: Clinical Role of RAD51 Testing in Triple-Negative Breast Cancer
ESMO Breast 2021: Safety Outcomes With Abemaciclib Plus Endocrine Therapy in Early Breast Cancer
Eribulin and Pembrolizumab Combination in Triple-Negative Breast Cancer
ASBrS 2021: Can Medicaid Expansion Improve Disparities in Breast Reconstruction?
APHINITY Trial Update: Adjuvant Pertuzumab-Based Therapy in Early HER2-Positive Breast Cancer
Treadmill and T Cells: Can Exercise Enhance Immune Responses in Breast Cancer?
Can Healthy Plant-Based Diets Decrease the Risk of Breast Cancer?
Predicting Response to Combination Therapies for Breast Cancer Brain Metastases
AACR 2021: Can Gut Microbiota Influence Treatment Response in Metastatic Breast Cancer
Distant Lymph Node Metastases From Breast Cancer: A Regional Disease?
AACR 2021: Using ctDNA Changes to Predict Response to Palbociclib-Based Therapy for Breast Cancer
AACR 2021: Talazoparib/Carboplatin Under Study in Triple-Negative Breast Cancer
Fixed-Dose Pertuzumab-Based Regimen Under Study in FeDeriCa Trial


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.